Delivery of muc1 mucin peptide by poly(d,/-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses

Journal of Pharmaceutical Sciences

Volumn 87, Issue 11, 1998, Pages 1421-1427

  Klmberley, D ^a   Sosnowski, Deborah L ^a   Kwon, Glen S ^a   Samuel, John ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; MICROSPHERE; MUC 1 MUCIN; PHOSPHORYL LIPID A; POLYGLACTIN; SYNTHETIC PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNOMODULATION; INTERFERON PRODUCTION; MICROENCAPSULATION; MOUSE; NONHUMAN; PARTICLE SIZE;

EID: 0031765186     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980070s     Document Type: Article

References (61)

1. Taylor-Papadimitriou, J.; Stewart, L.; Burchell, J.; Beverley, P. The polymorphic epithelial mucin as a target for immunotherapy. Ann. NYAcad. Sei. 1993, 690, 69-79.
2. Longenecker, B. M.; Maclean, G. D. Prospects for mucin epitopes in cancer vaccine. Immunologist 1993,1, 89-93.
3. Apostolopoulos, V.; McKenzie, I. F. C. Cellular mucins: Targets for immunotherapy. Grit. Rev. Immunol. 1994, 14, 293-309.
4. Samuel, J.; Longenecker, B. M. Development of active specific immunotherapeutic agents based on cancer-associated mucins. Pharm. Biotechnol. 1995, 6, 875-890.
5. Strous, G. J.; Dekker: J. Mucin-type glycoproteins. Crit. Rev. Biochem. Mol. Biol. 1992, 27, 57-92.
6. Devine, P. L.; McKenzie, I. F. C. Mucins: Structure, function and associations with malignancy. BioEssays 1992,14, 619625.
7. Gendler, S. J.; Lancaster, C. A.; Taylor-Papadimitriou, J.; Duhig, T.; Peat, N.; Burchell, J.; Pemberton, L.; Lalani, E.N.; Wilson, D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 1990, 265, 15286-15293.
8. Taylor-Papadimitriou, J.; Gendler, S. J. Molecular aspects of mucins. In Cancer Reviews; Hilgers, J., Zotter, S-, Eds.: Munksgaard: Copenhagen, Denmark, 1988; Vol. 11-12.
9. Finkelman, F. D.; Madden, K. B.; Cheever, A. W.; Katona, I. M.; Morris, S. C.; Gately, M. K.; Hubbard, B. R.; Gause, W. C.; Urban, J. F., Jr. Effects of interleukin 12 on the immune responses and host protection in mice infected with intestinal nematode parasites. J. Exp. Med. 1994, 179, 1563-1572.
10. Pearlman, E.; Kroeze, W. K.; Hazlett, F. E.; Chen, S. A.; Mawhorter, S. D.; Boom, W. H.; Kazura, J. W. Brugia malayi: Acquired resistance to microfilariae in Balb/c mice correlates with local Th2 responses. Exp. Parasita! 1993, 76' 200-208.
11. Keane-Myers, A.; Nickell, S. P. Role of IL-4 and IFN-yJn modulation of immunity to Borrelia burdorferi in mice. J. Immunol. 1995, 755, 2020-2028.
12. Scott, P.; Pearce, E.; Cheever, A. W.; Coffman, R. L.; Sher, A. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol. Rev. 1989, 112, 161-182.
13. Clerici, M.; Shearer, G. M. A Thl-Th2 switch is a critical step in the etiology of HIV infection. Immunol. Today 1993, 14, 107-111.
14. Mosmann, T. R. Cytokine patterns during the progression to AIDS. Science 1994, 265, 193-194.
15. Boon, T. Teaching the immune system to fight cancer. Sei. Am. 1993, 268, 82-89.
16. Nossal, G. J. V. Life, death and the immune system. Sei. Am. 1993, 269, 52-62.
17. Mosmann, T. R.; Coffman, R.L. Thl and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989, 7, 145-173.
18. Yamamura, M.; Uyemura, K.; Deans, R. J.; Weinberg, K; Rea, T. H.; Bloom, B. R.; Modlin, R. L. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 1991, 254, 277-279.
19. Tsicopoulos, A.; Hamid, Q.; Varney, V.; Ying, S.; Moqbel, R.; Durham, S. R.; Kay, A. B. Preferential messenger RNA expression of Thl-type cells (IFN-G+, IL-2+) in classical delayed-type (tuberculin) hypersensitivity reactions in human skin. J. Immunol. 1992, 148, 2058-2061.
20. Mosmann, T. R.; Cherwinski, H. M.; Bond, M. W.; Giedlin, M. A.; Coffman, R. L. Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136, 2348-2357.
21. Cherwinski, H. M.; Schumacher, J. H.; Brown, K. D.; Mosmann, T. R. Two types of mouse helper T cell clone III. Further differences in lymphokine synthesis between Thl and Th2 clones revealed by RNA hybridization, functionally monospecific biassays, and monoclonal antibodies. J. Exp. Med. 1987, 766, 1229-1244.
22. Del Prête, G. F.; Carli, M. D.; Mastrpmauro, C.; Biagiotti, R.; Macchia, D.; Falagiani, P.; Ricci, M.; Romagnani, S. Purified protein derivative ofMycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1T Helper or type 2 T Helper) profile of cytokine production. J. Clin. Invest. 1991, 88, 346-350.
23. Fiorentino, D. F.; Bond, M. W.; Mosmann, T. R. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Thl cells. J. Exp. Med. 1989, 770, 281-295.
24. O'Hagan, D. T.; McGee, J. P.; Holmgren, J.; Mowat, A. M.; Donachie, A. M.; Milla, K. H. G.; Gaisford, W.; Rahman, D.; Challcombe, S. J. Biodegradable microparticles for oral immunization. Vaccine 1993, 77, 149-154.
25. Maloy, K.; Donachie, A. M.; O'Hagan, D. T.; Mowat, A. M. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-coglycolide) microparticles. Immunology 1994, 81, 661-667.
26. Moore, A.; McGuirk, P.; Adams, S.; Jones, W. C.; McGee, J. P.; O'Hagan, D. T.; Mills, K. H. J. Immunization with a recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Thl cells. Vaccine 1995, 73, 1741-1749.
27. Partidos, C. D.; Vohra, P.; Anagnostopoulou, C.; Jones, D. H.; Farrar, G. H.; Steward, M. W. Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes. Mol. Immunol. 1996, 33, 485-491.
28. Newman, K. D.; Samuel, J.; Kwon, G. Ovalbumin peptide encapsulated in poly(d, 1 lactic-co-glycolic acid) microspheres is capable of inducing a T helper Type 1 immune response. J. Controlled Release, in press.
29. Ding, L.; Lalani, E.-N.; Reddish, M.; Koganty, R.; Wong, T.; Samuel, J.; Yacyshyn, M. B.; Meikle, A.; Fung, P. Y. S.; Taylor-Papadimitriou, J.; Longenecker, B. M. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 1993, 36, 9-17.
30. Urlich, J. T.; Myers, K. R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In Vaccine Design: The Subunit and Adjuvant Approach; Powell, M. F., Newman, M. J., Eds.; Plenum press: New York, 1995; pp 495-524.
31. Ogawa, Y.; Yamamoto, M.; Okada, H.; Yashiki, T.; Shimamoto, T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copolydactic/ glycolic) acid. Chem. Pharm. Bull. 1988, 36, 1095-1103.
32. Schreiber, R. D. Measurement of mouse and human interferony. In Current Protocols in Immunology; Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., Strober, W., Eds.; Green Publishing and Wiley-Interscience: New York, 1991; p 6.8.1.
33. Châtelain, R.; Varkila, K.; Coffman, R. L. IL-4 induces a Th2 response in Leishmania mo/or-infected mice. J. Immunol. 1992, 148, 1182-1187.
34. Mosmann, T. R. Measurement of mouse and human IL-10. In Current Protocols in Immunology; Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., Strober, W., Eds.; Green Publishing and Wiley-Interscience: New York, 1991; p 6.14.1.
35. Milich, D. R. Synthetic peptides: Prospects for vaccine development. Semin. Immunol. 1990, 2, 307-315.
36. Sanchez, Y.; lonescu-Matin, L; Dreesman, G. R.; Kramp, W.; Six, H. R.; Hollinger, F. B.; Mellnick, J. L. Humoral and cellular immunity to hepatitis B virus-derived antigen: Comparative activity of Freund's complete adjuvant, alum and liposome. Infect. Immun. 1980, 30, 728-733.
37. Childerstone. A.; Haron, J. A.; Lehner, T. T cell interaction generated by synthetic peptides covalently linked to a carrier. Eur. J. Immunol. 1989, 19, 169-176.
38. Apostolopoulos, V.; Xing, P. X.; McKenzie, I. F. Murine immune response to cells transfected with human MUC1: Immunization with cellular and synthetic antigens. Cancer Res. 1994, 54, 5186-5193.
39. Warren, H. S.; Chedid, L. A. Future prospects for vaccine adjuvants. Crit. Rev. Immunol. 1988, 8, 83-101.
40. Ertl, H. C. J.; Varga, I.; Xiang, Z. Q.; Kaiser, K.; Stephens, L.; Otvos, L., Jr. Poly(DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines. Vaccine 1996,14, 879-885.
41. Graham, R. A.; Burchell, J. M.; Beverley, P.; Taylor-Papadimitriou, J. Intramuscular immunization with MUC1 cDNA can protect C57 mice challenged with MUCl-expressing syngeneic mouse tumor cells. Int. J. Cancer 1996, 65, 664-670.
42. Pecher, G.; Finn, O. J. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc. Natl. Acad. Sei. U.S.A. 1996,53, 1699-1704.
43. Acrgs, R. B.; Hareuveni, M.; Balloul, J.-M.; Kieny, M.-P. Vaccinia virus MUC1 immunization of mice: Immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J. Immunother. 1993, 14, 136143.
44. Hareuveni, M.; Gautier, C.; Kieny, M.-P.; Wreschner, D.; Chambon, P.; Lathe, R. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc. Natl. Acad. Sei. U.S.A. 1990, 87, 9498-9502.
45. Apostolopoulos, V.; Pietersz, G. A.; McKenzie, I. F. C. Cellmediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996, 14, 930-938.
46. Samuel, J.; Budzynski, W. A.; Reddish, M. A.; Ding, L.; Zimmermann, G. L.; Krantz, M. J.; Koganty, R. R.; Longenecker, B. M. Immunogenicity and antitumor activity of a liposomal MUC1 peptide based vaccine. Int. J. Cancer, in press.
47. Guan, H. H.; Budzynski, W.; Koganty, R.; M. J., K.; Reddish, M. A.; Rogers, J. A.; Longenecker, B. M.; Samuel, J. Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses. Bioconjugate Chem., in press.
48. Snapper, C. M.; Paul, W. E. Interferon-y and B cell stimulatory factor-1 reciprocally regulate IgG isotype production Science 1987, 236, 944-947.
49. Query, J. C.; Galbiati, F.; Smiroldo, S.; Adorini, L. Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and /?2-microglobulin-deficient BALB/c mice. J. Exp. Med. 1996, 183, 485-497.
50. Germann, T.; Bongartz, M.; Dlugonska, H.; Hess, H.; Schmitt, E.; Kolbe, L.; Kölsch, E.; Podlaski, F. J.; Gately, M. K; Rude, E. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur. J. Irnmunol. 1995,25,823829.
51. Snapper, C. M.; Mclntyre, T. M.; Handler, R.; Pecanha, L. M. T.; Finkelman, F. D.; Lees, A.; Mond, J. J. Induction of IgG3 sretion by Interferon y: A model for T cell-independent class switching in response to T cell-independent type 2 antigens. J. Exp. Med. 1992, 775, 1367-1371.
52. Parish, C. R. The relationship between humoral and cellmediated immunity. Trans. Rev. 1972, 13, 35-66.
53. Bretscher, P. A.; Wei, G.; Menon, J. N.; Bielefedt-Ohmann, H. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 1992, 257, 539-542.
54. Kuby, J. Immunology, 2nd ed.; Freeman and Company: New York, 1994.
55. Gengoux, C.; Leclerc, C. In vivo induction of CD4+ T cell responses by antigens covalently linked to synthetic microspheres does not require adjuvant. Int. Immunol. 1995, 7, 45-53.
56. Sedlik, C.; Deriaud, E.; Leclerc, C. Lack of T(h)l or T(h)2 polarization of CD4 (+) T cell response induced by particulate antigen targeted to phagocytic cells. Int. Immunol. 1997, 9, 91-103.
57. Mosmann, T. R.; Sad, S. The expanding universe of T cell subsets: Thl, Th2 and more. Immunol. Today 1996, 17, 138-146.
58. Peat, N.; Gendler, S. J.; Lalani, E.-N.; Duhig, T.; TaylorPapadimitriou, T. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res. 1992,52, 1954-1960.
59. Gilewski, T.; Adluri, R.; Zhang, S.; Houghton, A.; Norton, L.; Livingston, P. Preliminary results: vaccination of breast cancer patients (PTS) lacking identifiable disease (NED) with MUC-1-keyhole limpet hemocyanin (KLH) conjugate and QS21. Proc. ASCO 1996, 75, 555.
60. Goydos, J. S.; Elder, E.; Whiteside, T. L.; Finn, O. J.; Lotze, M. T. A phase I trial of a synthetic mucin peptide vaccine. J. Surg. Res. 1996, 63, 298-304.
61. Longenecker, B. M.; Reddish, M. A.; Koganty, R. R.; Budzynski, W.; Ding, L.; Maclean, G. D. Cancer vaccines which target carbohydrate, glycopeptide and peptide mucin epitopes. Presented at the Cambridge Symposia, Discovery and Development of Tumor Vaccines. Taos, NM, 1996.